Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

If the U.S. Food and Drug Administration agrees to allow Novo Nordisk to expand the prescription’s label, Wegovy would become the first oral GLP-1 treatment for obesity management.

the maker of the weight-loss drug Wegovy. San Francisco-based Hims & Hers said the plan was to make obesity care “more accessible, more affordable and more connected” for Americans.

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare ...

CVS Caremark to list Wegovy as preferred GLP-1 drug on top formularies starting July 1, 2025. Novo Nordisk plans continued collaboration with CVS to widen Wegovy access. Unlock your all-in-one ...

Novo Nordisk's Wegovy, a weight loss drug, will soon be accessible to US customers via telehealth platforms like Hims & Hers, LifeMD, and Ro, offering a reduced monthly price of $449. Novo Nordisk ...

By Dani Blum I’ve reported on Ozempic since 2022. New research shows that semaglutide, the compound in the weight-loss drug Wegovy, could treat an increasingly common liver disease. The study ...

Novo Nordisk works with Hims & Hers, Ro, LifeMD to expand Wegovy access Hims & Hers, LifeMD shares jump more than 25% and 36% respectively Danish drugmaker says move is "very clear message" Wegovy ...